SMTL ID : 8hlt.1 (1 other biounit)

The co-crystal structure of DYRK2 with YK-2-99B

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 2.80 Å

Oligo State

monomer

Ligands

1 x XSE: (6-{[(4P)-4-(1,3-benzothiazol-5-yl)-5-fluoropyrimidin-2-yl]amino}pyridin-3-yl)(piperazin-1-yl)methanone(Non-covalent)

XSE.1: 17 residues within 4Å: Chain A: I.84, G.85, F.89, V.92, A.105, I.141, F.157, E.158, L.159, L.160, S.161, M.162, N.163, E.166, L.211, I.223, D.224 6 PLIP interactions: 6 interactions with chain A Hydrophobic interactions: A:I.84, A:V.92, A:I.223 Hydrogen bonds: A:L.160, A:L.160, A:N.163

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Yuan, K. et al., Discovery of Potent DYRK2 Inhibitors with High Selectivity, Great Solubility, and Excellent Safety Properties for the Treatment of Prostate Cancer. J.Med.Chem. (2023)

Release Date

2023-12-13

Peptides

Dual specificity tyrosine-phosphorylation-regulated kinase 2: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Dual specificity tyrosine-phosphorylation-regulated kinase 2

Related Entries With Identical Sequence